George Song Portfolio
Invests via Superstring Capital Management LP | Managed by George Song
Invests via Superstring Capital Management LP
Managed by George Song
Automatically Tracked
George Song Profile
A seasoned entrepreneur and investor, George Song has made a significant mark in the technology startup landscape. With a career focused on innovative business solutions, he brings deep operational expertise and visionary leadership to emerging companies. His background includes founding successful ventures that leverage cutting-edge technologies, driving substantial growth and market expansion. George’s role as an active investor enables him to nurture budding talent while fostering collaboration across various sectors. With his comprehensive understanding of entrepreneurial dynamics and capital markets, he is well-positioned to identify lucrative opportunities within fast-evolving industries.
A seasoned entrepreneur and investor, George Song has made a significant mark in the technology startup landscape. With a career focused on innovative business solutions, he brings deep operational expertise and visionary leadership to emerging companies. His background includes founding successful ventures that leverage cutting-edge technologies, driving substantial growth and market expansion. George’s role as an active investor enables him to nurture budding talent while fostering collaboration across various sectors. With his comprehensive understanding of entrepreneurial dynamics and capital markets, he is well-positioned to identify lucrative opportunities within fast-evolving industries.
Investment Philosophy & Strategy
In a rapidly evolving technology landscape, investment opportunities are abundant for visionary leaders. George Song is well-versed in identifying and cultivating the next wave of innovative startups. His unique approach combines operational know-how with an entrepreneurial mindset, enabling a keen assessment of business models that demonstrate scalability. By fostering synergistic partnerships within the ecosystem, he aims to amplify growth trajectories while optimizing resource allocation. With an emphasis on sectors at the forefront of disruption, his strategy prioritizes agility and market responsiveness as pivotal components for sustainable success.
In a rapidly evolving technology landscape, investment opportunities are abundant for visionary leaders. George Song is well-versed in identifying and cultivating the next wave of innovative startups. His unique approach combines operational know-how with an entrepreneurial mindset, enabling a keen assessment of business models that demonstrate scalability. By fostering synergistic partnerships within the ecosystem, he aims to amplify growth trajectories while optimizing resource allocation. With an emphasis on sectors at the forefront of disruption, his strategy prioritizes agility and market responsiveness as pivotal components for sustainable success.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
74.24%
Gain -2.07%
Monthly
1.83%
Yearly
24.32%
Drawdown
47.44%
$173.37M
Equity
Holdings
$173.37M
Investment
$129.77M
$64.09M
Profit -$3.32M
Realized
$20.48M
Unrealized
$43.6M
Dividends
$132,767.92
Goals
Avg. 100% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-2.07%
Profit
-$3.32M
Win %
76%
This Week
Compared To Last Week
Gain
-1.87%
Profit
-$3.31M
Win %
76%
This Month
Compared to last month
Gain
0.94%
Profit
$1.61M
Win %
76%
This Year
Compared to last year
Gain
23.87%
Profit
$33.4M
Win %
81%
ANL Adlai Nortye Ltd. ADR
+3.9%
+$186,683.4 
BMEA Biomea Fusion, Inc.
+2.34%
+$7,500 
URGN Urogen Pharma Ltd.
+2.21%
+$344,760.19 
ZLAB Zai Lab Ltd.
+1.58%
+$88,261.76 
CLDX Celldex Therapeutics Inc.
+0.2%
+$12,603.36 
ARVN Arvinas Inc.
+0.12%
+$3,126.2 
TRVI Trevi Therapeutics Inc.
-12.06%
-$578,601.8 
TNXP Tonix Pharmaceuticals Holding Corp
-11.66%
-$92,133 
SION Sionna Therapeutics Inc.
-7.53%
-$524,609.28 
PTN Palatin Technologies, Inc.
-6.71%
-$21,941.09 
TSHA Taysha Gene Therapies Inc.
-6.38%
-$98,142.22 
MPLT MapLight Therapeutics, Inc.
-4.96%
-$361,221.32 
CLYM Climb Biotherapeutics, Inc.
-3.78%
-$95,620.32 
AXSM Axsome Therapeutics, Inc.
-3.63%
-$93,774.12 
DFTX Definium Therapeutics, Inc.
-3.36%
-$523,676.89 
ORIC Oric Pharmaceuticals Inc.
-2.89%
-$35,722.54 
CABA Cabaletta Bio Inc.
-2.83%
-$85,299.12 
GMAB Genmab A/S Sponsored ADR
-2.82%
-$159,334.29 
IPSC Century Therapeutics, Inc.
-2.67%
-$7,158.48 
SMMT Summit Therapeutics Inc.
-2.25%
-$276,790.63 
TVTX Travere Therapeutics Inc.
-2.19%
-$127,414.96 
VIR Vir Biotechnology Inc.
-2.12%
-$146,109.6 
COGT Cogent Biosciences, Inc.
-2%
-$175,623.24 
DRUG Bright Minds Biosciences Inc.
-1.98%
-$20,099.61 
ACRS Aclaris Therapeutics, Inc.
-1.94%
-$40,313.9 
PCVX Vaxcyte, Inc.
-1.25%
-$77,317.8 
PFE Pfizer Inc.
-1.22%
-$22,570 
UTHR United Therapeutics Corporation
-1.18%
-$32,827.38 
IQV IQVIA Holdings Inc.
-1.12%
-$59,292.82 
ORKA Oruka Therapeutics, Inc.
-1.09%
-$64,226.91 
CGEM Cullinan Therapeutics, Inc.
-1.07%
-$11,301.96 
VRTX Vertex Pharmaceuticals Incorporated
-1.06%
-$56,701.5 
IMVT Immunovant Inc.
-0.84%
-$121,586.04 
TARA Protara Therapeutics Inc.
-0.73%
-$3,643.71 
SVRA Savara Inc.
-0.54%
-$47,579.31 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 332 | Longs Won 125/332 37% | Profit Factor 1.88 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $1.62M |
| Average Win $1.1M | Best Trade (Mar 30) $15.47M | Sharpe Ratio -42.58 |
| Average Loss -$352,876.07 | Worst Trade (Mar 30) -$5.19M | Z-Score -2.5 (100%) |
| Commissions $0 | Avg. Trade Length 6m 2d | Expectancy $193,028.11 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.01% | 0.36% | 7.01% |
| Consecutive Losing Trades | 491 | 442 | 393 | 344 | 295 | 246 | 197 | 147 | 98 | 49 |
Hover over the desired column for a detailed explanation.
Returns
Overall, MonthlyNo Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for George Song?
The largest contributions to the portfolio's profits come from the following stocks: Terns Pharmaceuticals, Inc - $24.22M, Cidara Therapeutics, Inc - $8.57M, Cogent Biosciences, Inc - $8.03M, NovoCure Ltd - $5.46M, and Zai Lab Ltd - $4.94M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Cytokinetics, Incorporated - $9.73M, Nkarta Inc - $5.58M, Marinus Pharmaceuticals Inc - $5.3M, Instil Bio, Inc - $5.19M, and Structure Therapeutics Inc - $3.81M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does George Song's portfolio generate?
The portfolio generates substantial dividend income, with a total of $132,767.92 earned over time. The largest contributors to dividend income include Pfizer Inc - $116,170.52, So-Young International Inc - $10,964.52, and Regeneron Pharmaceuticals, Inc - $5,632.88. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are George Song's monthly returns?
George Song's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can George Song's strategy be considered aggressive or moderate?
George Song's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow George Song's strategy?
George Song's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
